Adverse events were observed in essentially every dose group in the single-dose psilocybin trial, with higher incidence and severity in the 25-milligram group, ranging from mild transient side effects like headaches and anxiety to severe effects including suicidal ideation, illustrating the dose-response curve for both benefits and risks.
factualpending
Speaker
Andrew HubermanEvidence Quote
“there were adverse events in essentially every group...The number of adverse events was highest in the 25-milligram dose group...With higher dosages, there tends to be greater relief from depressive symptoms, but also a greater chance for adverse events. Some of those adverse events can be quite severe. So feelings of suicidal ideation”
Created: 8/12/2026, 6:37:08 PM
Your notes
Loading notes...